Skip to main content
PCRX
NASDAQ Life Sciences

新数据显示Pacira的EXPAREL降低门诊骨科手术的医疗成本和阿片类药物使用

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$23.79
Mkt Cap
$963.255M
52W Low
$18.8
52W High
$27.64
Market data snapshot near publication time

summarizeSummary

Pacira BioSciences在AMCP 2026会议上提出有力的真实世界数据，证明其旗舰非阿片类止痛疗法EXPAREL与门诊全髋和全膝关节置换手术中的较低总医疗成本和降低阿片类药物使用量有关。特别地，EXPAREL的使用在手术后3和6个月内显示出较低的总医疗成本，并在某些患者人群中显著降低了6个月后的阿片类药物使用量。这些发现为EXPAREL提供了强有力的经济和临床论据，强调了它对医疗提供者和支付者的价值主张。这种积极的数据对于推动进一步的市场采用和加强Pacira在非阿片类止痛管理领域的竞争地位至关重要，建立在该公司最近的强劲财务表现之上。

在该公告发布时，PCRX的交易价格为$23.79，交易所为NASDAQ，所属行业为Life Sciences，市值约为$9.6亿。 52周交易区间为$18.80至$27.64。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed PCRX - Latest Insights

PCRX
Apr 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
EXPAREL Real-World Data Reveals Significant Opioid Reduction, Lower Medical Costs for Medicare Hip Patients
Sentiment: Positive
View Wiseek Article
PCRX
Apr 17, 2026, 4:15 PM EDT
Filing Type: PREC14A
Importance Score:
8
Pacira BioSciences Faces Contested Director Election and Seeks Approval for Significant Equity Plan Expansion Amidst Activist Pressure
Sentiment: Negative
View Wiseek Article
PCRX
Apr 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
New Data Shows Pacira's EXPAREL Lowers Healthcare Costs, Opioid Use in Outpatient Orthopedic Surgeries
Sentiment: Positive
View Wiseek Article
PCRX
Mar 12, 2026, 7:57 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Activist DOMA Perpetual Nominates Directors, Demands CEO Replacement and Company Sale
Sentiment: Negative
View Wiseek Article
PCRX
Mar 11, 2026, 5:02 PM EDT
Source: GlobeNewswire
Importance Score:
8
Pacira Counters Activist Investor, Highlights Strategic Progress and Shareholder Returns
Sentiment: Neutral
View Wiseek Article
PCRX
Mar 11, 2026, 3:25 PM EDT
Filing Type: DFAN14A
Importance Score:
9
Activist DOMA Perpetual Nominates Directors, Demands CEO Replacement & Formal Sale Process for Pacira BioSciences
Sentiment: Negative
View Wiseek Article
PCRX
Mar 11, 2026, 1:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Activist Investor Demands Pacira CEO Replacement, Cites IP Battle Risks
Sentiment: Negative
View Wiseek Article
PCRX
Feb 26, 2026, 4:16 PM EST
Filing Type: 10-K
Importance Score:
9
Pacira BioSciences Returns to Profitability in 2025 with Strong Revenue Growth and Strategic Progress
Sentiment: Positive
View Wiseek Article
PCRX
Feb 26, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
9
Pacira BioSciences Reports Strong 2025 Turnaround, Significant Share Repurchases, and Positive 2026 Outlook
Sentiment: Positive
View Wiseek Article
PCRX
Jan 28, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
Pacira BioSciences Appoints Dr. Samit Hirawat to Board Amidst Activist Investor Pressure
Sentiment: Positive
View Wiseek Article